1 INTRODUCTION

Vernal keratoconjunctivitis (VKC) is a severe ocular disease characterized by recurring acute and/or chronic corneal‐conjunctival inflammation leading to visual sequelae.¹ Since no treatments are universally effective in the management of VKC, novel therapies are currently under investigation, including anti‐immunoglobulin E (IgE). Although the efficacy and safety of omalizumab have been assessed in the therapeutic management of IgE‐mediated disorders^2-7; literature data on the use of omalizumab in VKC are very sparse.^8-13 Herein, we reported the use of omalizumab in treating conventional treatment‐resistant VKC unresponsive in two children. Finally, an overview of the available literature data is also reported.

中文翻译：

---

奥马珠单抗治疗传统治疗难治性春季角结膜炎的临床疗效和安全性：我们的经验和文献综述

 1 简介

春季角结膜炎（VKC）是一种严重的眼部疾病，其特征是反复发作的急性和/或慢性角膜结膜炎症，导致视力后遗症。 ¹由于尚无治疗 VKC 的普遍有效方法，目前正在研究新疗法，包括抗免疫球蛋白 E (IgE)。尽管奥马珠单抗的有效性和安全性已在 IgE 介导的疾病的治疗管理中得到评估^2-7 ；关于在 VKC 中使用奥马珠单抗的文献数据非常稀疏。 ^8-13在此，我们报告了使用奥马珠单抗治疗两名对常规治疗无反应的儿童的耐药 VKC。最后，还报告了现有文献数据的概述。